Latest News and Press Releases

Actimab-MDS to be featured in a Product Theater on February 21st  Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of...

• Conference call to be held on Tuesday, February 13th, 2018 at 4:30 PM ET to discuss planned Phase 1 clinical trial with Dr. Ehab Atallah • New trial represents expansion of Actinium’s CD33 program...

• To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement timing  • Actinium’s executive management and...

- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb  - Global leader with deep expertise in...

- Record date established as February 14, 2018  - To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement...

- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A  - Combination aligns with Actinium’s focus on improving bone marrow transplant access...

NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...

NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...

- Poster to present additional data showcasing ability of Actinium’s AWE Technology to yield a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma NEW YORK,...

Strong finish to 2017 sets stage for series of value enhancing milestones in 2018 NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the...